Related Experiment Videos
Nonmedication smoking reduction program for inpatients with chronic schizophrenia: a randomized control design study.
Marc Gelkopf1, Sigalit Noam, Dimitri Rudinski
1Department of Community Mental Health, University of Haifa, Haifa, Israel. emgelkopf@013.net.il
The Journal of Nervous and Mental Disease
|February 3, 2012
Summary
Behavioral interventions significantly reduced smoking in hospitalized schizophrenia patients. This smoking reduction did not negatively impact clinical status or weight.
Area of Science:
- Psychiatry
- Addiction Medicine
- Behavioral Health
Background:
- Individuals with schizophrenia exhibit higher smoking rates than the general population.
- Hospitalized patients with schizophrenia smoke more frequently than community-dwelling individuals.
- Smoking cessation is a significant challenge in schizophrenia treatment.
Purpose of the Study:
- To assess the efficacy of a behavioral group smoking reduction intervention for chronic hospitalized schizophrenia patients.
- To evaluate the intervention's impact on smoking behavior, clinical status, quality of life, and weight.
Main Methods:
- A controlled study randomly assigned chronic schizophrenia inpatients to a five-session smoking reduction intervention or a waiting list.
- Self-reported smoking, clinical status (using PANSS, HAM-D, CGI-P), quality of life (Q-LES-Q-SV), and weight were assessed pre- and post-intervention (3 months).
Main Results:
- The intervention group showed a significant reduction in the number of cigarettes smoked compared to the waiting list group.
- No significant worsening in clinical status (psychosis, depression) was observed.
- No significant weight gain was associated with the intervention.
Conclusions:
- Behavioral group-oriented smoking reduction interventions are effective in reducing smoking among hospitalized chronic schizophrenia patients.
- These interventions can be implemented without adverse effects on clinical status or weight.
- Smoking reduction programs should be considered for this vulnerable population.
Related Concept Videos
01:29Chronic Obstructive Pulmonary Disease-V: Management
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...